MHRA批准Retifanlimab(ZYNYZ)用于治疗晚期肛门癌
正文 · 中文译文
新闻稿 MHRA批准Retifanlimab(ZYNYZ)用于治疗晚期肛门癌 药品和健康产品管理局(MHRA)已批准retifanlimab(ZYNYZ)用于治疗成人肛管鳞状细胞癌(SCAC)。 来源: 药品和健康产品管理局 发布时间: 2026年11月11日 药品和健康产品管理局(MHRA)已批准retifanlimab(ZYNYZ)用于治疗成人肛管鳞状细胞癌(SCAC),这是一种无法通过手术切除且已转移或已在原发癌同一区域复发的肛门癌。 MHRA此前于2026年7月6日批准retifanlimab用于治疗成人晚期梅克尔细胞癌(MCC)——一种罕见、侵袭性强的皮肤癌。 Retifanlimab与卡铂和紫杉醇(均为化疗药物)联合使用,通过帮助机体免疫系统识别并攻击癌细胞发挥作用。它阻断癌细胞用以逃避免疫系统检测的一条通路,使免疫细胞能够更好地识别和摧毁癌细胞。 运营执行主任Julian Beach表示: “晚期肛门癌患者需要经过仔细评估的治疗方案。 “该批准为癌症无法通过手术切除、或已扩散至身体其他部位、或已返回同一区域的成人提供了一种新的治疗选择。” “与所有药物一样,随着retifanlimab更广泛地使用,我们将继续密切监测其安全性和有效性。” Retifanlimab通过静脉输注给药,输注时间约30分钟,每四周一次。在最初六个治疗周期中,它与卡铂和紫杉醇联合给药。 在一项纳入308例转移性或局部晚期肛管鳞状细胞癌患者的研究中,与安慰剂联合化疗相比,retifanlimab联合化疗在延长患者无癌症恶化生存时间方面更为有效。 有关本药报告的全部副作用清单,请参见患者信息手册(PIL)第4节或MHRA网站上可获取的产品特性摘要(SmPC)。 致编辑的说明 该批准于2026年11月5日授予Incyte Biosciences UK Ltd。 本产品通过国际认可程序(IRP)提交并获批。 更多信息可在产品特性摘要和患者信息手册中查阅,这些文件将在批准后7天内发布于MHRA产品网站。 药品和保健产品监管局(MHRA)负责通过确保所有药品和医疗器械有效且具有可接受的安全性,来监管英国的所有药品和医疗器械。我们的所有工作均以稳健且基于事实的判断为基础,以确保获益足以证明任何风险是合理的。 MHRA是卫生和社会关怀部的执行机构。 媒体咨询请联系 newscentre@mhra.gov.uk 或致电 020 3080 7651。
正文 · 英文原文
News story MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced anal cancer The Medicines and Healthcare products Regulatory Agency (MHRA) has approved retifanlimab (ZYNYZ) for the treatment of adults with squamous cell carcinoma of the anal canal (SCAC). From: Medicines and Healthcare products Regulatory Agency Published: 11 November 2026 The Medicines and Healthcare products Regulatory Agency (MHRA) has approved retifanlimab (ZYNYZ) for the treatment of adults with squamous cell carcinoma of the anal canal (SCAC), a type of anal cancer that cannot be removed by surgery and is metastatic or has come back in the same area as the original cancer. The MHRA previously approved retifanlimab on July 6, 2026 for the treatment of adults with advanced Merkel cell carcinoma (MCC) - a rare, aggressive type of skin cancer. Retifanlimab is used in combination with carboplatin and paclitaxel, which are chemotherapy medicines, and works by helping the body’s immune system recognise and attack cancer cells. It blocks a pathway that cancer cells can use to avoid being detected by the immune system, allowing immune cells to better identify and destroy them. Julian Beach, Executive Director, Operations, said: “People living with advanced anal cancer need treatments that have been carefully assessed. “This approval provides a new treatment option for adults whose cancer cannot be removed by surgery or has spread to other parts of the body or returned to the same area. “As with all medicines, we will continue to closely monitor the safety and effectiveness of retifanlimab as it is used more widely.” Retifanlimab is administered via intravenous infusion over around 30 minutes, once every four weeks. For the first six treatment cycles, it is given together with carboplatin and paclitaxel. In a study of 308 people with metastatic or locally advanced squamous cell carcinoma of the anal canal, retifanlimab given with chemotherapy was more effective than placebo given with chemotherapy, at increasing the amount of time people lived without their cancer getting worse. For the full list of all side effects reported with this medicine, see Section 4 of the Patient Information Leaflet (PIL) or the Summary of Product Characteristics (SmPC) available on the MHRA website. Notes to editors The approval was granted on 5 November 2026 to Incyte Biosciences UK Ltd. This product was submitted and approved via International Recognition Procedure (IRP). More information can be found in the Summary of Product Characteristics and Patient Information Leaflets which will be published on the MHRA Products website within 7 days of approval. The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe. All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks. The MHRA is an executive agency of the Department of Health and Social Care. For media enquiries, please contact newscentre@mhra.gov.uk or call 020 3080 7651.